Guizhou Bailing Group Pharmaceutical Co Ltd (SHE:002424) — Market Cap & Net Worth
Market Cap & Net Worth: Guizhou Bailing Group Pharmaceutical Co Ltd (002424)
Guizhou Bailing Group Pharmaceutical Co Ltd (SHE:002424) has a market capitalization of $1.03 Billion (CN¥7.03 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #8983 globally and #2390 in its home market, demonstrating a -0.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Bailing Group Pharmaceutical Co Ltd's stock price CN¥5.03 by its total outstanding shares 1397598400 (1.40 Billion). Analyse 002424 operating cash flow to see how efficiently the company converts income to cash.
Guizhou Bailing Group Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guizhou Bailing Group Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $5.00 Billion to $1.03 Billion (-13.27% CAGR).
Guizhou Bailing Group Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Bailing Group Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Guizhou Bailing Group Pharmaceutical Co Ltd's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
23.42x
Guizhou Bailing Group Pharmaceutical Co Ltd's market cap is 23.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.00 Billion | $1.90 Billion | $411.37 Million | 2.63x | 12.15x |
| 2016 | $3.71 Billion | $2.21 Billion | $482.33 Million | 1.67x | 7.68x |
| 2017 | $3.03 Billion | $2.59 Billion | $526.14 Million | 1.17x | 5.76x |
| 2018 | $1.73 Billion | $3.14 Billion | $563.24 Million | 0.55x | 3.07x |
| 2019 | $1.74 Billion | $2.85 Billion | $282.75 Million | 0.61x | 6.14x |
| 2020 | $1.60 Billion | $3.09 Billion | $152.38 Million | 0.52x | 10.51x |
| 2021 | $1.55 Billion | $3.11 Billion | $118.48 Million | 0.50x | 13.12x |
| 2022 | $1.67 Billion | $3.54 Billion | $138.47 Million | 0.47x | 12.05x |
| 2023 | $1.66 Billion | $4.26 Billion | -$414.51 Million | 0.39x | N/A |
| 2024 | $787.37 Million | $3.83 Billion | $33.62 Million | 0.21x | 23.42x |
Competitor Companies of 002424 by Market Capitalization
Companies near Guizhou Bailing Group Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Guizhou Bailing Group Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Guizhou Bailing Group Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guizhou Bailing Group Pharmaceutical Co Ltd's market cap moved from $5.00 Billion to $ 1.03 Billion, with a yearly change of -13.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.03 Billion | +15.63% |
| 2025 | CN¥889.63 Million | +12.99% |
| 2024 | CN¥787.37 Million | -52.53% |
| 2023 | CN¥1.66 Billion | -0.61% |
| 2022 | CN¥1.67 Billion | +7.37% |
| 2021 | CN¥1.55 Billion | -2.94% |
| 2020 | CN¥1.60 Billion | -7.77% |
| 2019 | CN¥1.74 Billion | +0.30% |
| 2018 | CN¥1.73 Billion | -42.83% |
| 2017 | CN¥3.03 Billion | -18.30% |
| 2016 | CN¥3.71 Billion | -25.82% |
| 2015 | CN¥5.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Guizhou Bailing Group Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more